Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on November 12, 2024. The filing serves to announce the Company's financial results for the three and nine months ended September 30, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced Exhibit 99.1 press release, which is not included in the input content.
Material Changes
No material changes versus prior periods are detailed in this specific document. The filing solely references the issuance of the press release containing the comparative financial results.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Oncocyte Corporation (Ticker: OCX), as the input metadata incorrectly listed "Insight Molecular Diagnostics Inc."
- Access Exhibit 99.1 (the press release dated November 12, 2024) to obtain actual revenue, net income, and cash flow figures.
- Confirm the reporting period covers the three and nine months ended September 30, 2024.
- Note that this 8-K filing itself does not constitute a "filed" document for liability purposes under Section 18 of the Exchange Act regarding the financial data.